Trieza Therapeutics is a new company developing immunomodulatory oncolytic viruses for the treatment of cancer. Founded as a spin-out from Potenza Therapeutics, Trieza has a portfolio containing multiple pre-clinical candidates.
Trieza Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Trieza Therapeutics, is developing immunomodulatory oncolytic viruses that attack cancer cells.
In Dec 2016, Abzena PLC has granted Trieza an exclusive worldwide, royalty-bearing licence to an undisclosed antibody sequence,
created using Abzenas Composite Human Antibody technology. Under the terms, Abzena will receive up to USD35.0 Mn in development and commercial milestone, plus further royalties on the sale of licensed products.